Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP4 | P49662 | 1/20 | 0.33 |
| ▸ | CASP5 | P51878 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172195 | 1.00 | CHRM5 (0.52) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4184118 | 0.89 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4184117 | 0.89 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4239136 | 0.88 | CHRM5 (0.59) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL2249609 | 0.86 | CHRM5 (0.62) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL41997 | 0.84 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL3557098 | 0.81 | CHRM5 (0.54) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL2252156 | 0.77 | — | — | |
| SCHEMBL3554561 | 0.75 | ALDH1A1 (0.40) | CHRM5ADRA2CACHE | |
| SCHEMBL2225393 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | CHRM5 775/4885ADRA2C 179/4885ACHE 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.